AUS
NZ
UK
CA
USA
IND
Highlights
- Anatara Lifesciences (ANR) completes participant recruitment for Stage 2 of its IBS treatment trial.
- Recruitment spans four sites across Australia with screening set to continue.
- Headline results anticipated in the first quarter of 2025.
Anatara Lifesciences (ASX:ANR) has successfully enrolled the required 60 participants for Stage 2 of its critical trial, assessing the effectiveness of its Gastrointestinal ReProgramming (GaRP) candidate for irritable bowel syndrome (IBS). This milestone comes ahead of the company’s projected completion timeline.
Among the participants, over 25 individuals have reached the final stages of screening, representing a diverse group of potential candidates. While no additional recruitment is planned beyond December 13, screening will remain open for the shortlisted candidates to ensure they meet the criteria for sub-types such as IBS-Diarrhoeal predominant and IBS Mixed patterns.
The recruitment process spanned four trial sites located in the eastern mainland states of Australia and Adelaide. This geographical diversity aims to provide robust and inclusive data for the trial. Anatara expects headline readouts from Stage 2 to be available by the first quarter of 2025, a critical step in advancing the GaRP program.
Executive Chair Dr. David Brookes shared insights into the recruitment progress, expressing satisfaction with the pace and quality of enrollment. He emphasized the importance of this stage in delivering meaningful data for IBS sufferers.
Recruitment is set to pause next week, and the company will evaluate whether resumption is necessary in early 2025. Dr. Brookes urged eligible IBS sufferers who meet the trial criteria to register their interest promptly, highlighting the limited timeframe for participation. Potential participants can visit Anatara’s website or use the dedicated ibstrial.au platform to connect with the clinic in their area for screening and enrollment.
The company’s focus on IBS treatment aims to address significant unmet needs in managing this condition, which impacts a substantial portion of the population. With Stage 2 recruitment completed, Anatara continues to advance its mission of delivering innovative therapeutic solutions.
On the market front, Anatara (ASX:ANR) was trading at 5.5 cents as of 13:00 AEDT, marking a slight decline of 3.51% since the market opened. Despite this fluctuation, the milestone achievement positions the company for a promising trajectory in the coming months.
As the first quarter of 2025 approaches, all eyes will be on the upcoming results from the GaRP trial, which could pave the way for further advancements in IBS treatment.
